Aprea Therapeutics, Inc. (APRE)
$0.87+$0.01 (+1.59%) Today
Richard Peters - DirectorRichard Peters - Director
Oren Gilad - OfficerOren Gilad - OfficerAprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 16 | 125,520 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
24 Form 4 filings on record, the earliest from Oct 15, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Michael Grissinger - Director | Grant or award | Stock Options (Right to Buy) | 12,555 | $0.00 | - | |
| Michael Grissinger - Director | Grant or award | Common Stock | 3,135 | $0.00 | - | |
| Gabriela Gruia - Director | Grant or award | Common Stock | 3,135 | $0.00 | - | |
| Gabriela Gruia - Director | Grant or award | Stock Options (Right to Buy) | 12,555 | $0.00 | - | |
| Richard Peters - Director | Grant or award | Common Stock | 3,135 | $0.00 | - | |
| Richard Peters - Director | Grant or award | Stock Options (Right to Buy) | 12,555 | $0.00 | - | |
| John B. Henneman III - Director | Grant or award | Common Stock | 3,135 | $0.00 | - | |
| John B. Henneman III - Director | Grant or award | Stock Options (Right to Buy) | 12,555 | $0.00 | - | |
| Jean-Pierre Bizzari - Director | Grant or award | Common Stock | 3,135 | $0.00 | - | |
| Jean-Pierre Bizzari - Director | Grant or award | Stock Options (Right to Buy) | 12,555 | $0.00 | - | |
| Marc Duey - Director | Grant or award | Stock Options (Right to Buy) | 12,555 | $0.00 | - | |
| Marc Duey - Director | Grant or award | Common Stock | 3,135 | $0.00 | - | |
 Rifat Pamukcu - Director | Grant or award | Common Stock | 3,135 | $0.00 | - | |
| Rifat Pamukcu - Director | Grant or award | Stock Options (Right to Buy) | 12,555 | $0.00 | - | |
| Bernd R. Seizinger - Director | Grant or award | Stock Options (Right to Buy) | 12,555 | $0.00 | - | |
| Bernd R. Seizinger - Director | Grant or award | Common Stock | 3,135 | $0.00 | - | |
| John P. Hamill - Officer | Open-market purchase | Pre-Funded Warrant | 30,978 | $0.81 | $25K | |
| John P. Hamill - Officer | Open-market purchase | Common Warrant | 30,978 | - | - | |
| Richard Peters - Director | Open-market purchase | Pre-Funded Warrant | 123,915 | $0.81 | $100K | |
| Richard Peters - Director | Open-market purchase | Common Warrant | 123,915 | - | - | |
| Oren Gilad - Officer | Grant or award | Common Stock | 20,175 | $0.00 | - | |
| Oren Gilad - Officer | Grant or award | Stock Options (Right to Buy) | 80,700 | $0.00 | - | |
| John P. Hamill - Officer | Grant or award | Common Stock | 10,095 | $0.00 | - | |
| John P. Hamill - Officer | Grant or award | Stock Options (Right to Buy) | 40,380 | $0.00 | - | |
| Oren Gilad - Officer | Open-market purchase | Common Stock | 28,100 | $0.89 | $25K | |
| Oren Gilad - Officer | Open-market purchase | Common Warrant | 28,100 | - | - | |
| John P. Hamill - Officer | Open-market purchase | Common Stock | 5,700 | $0.89 | $5K | |
| John P. Hamill - Officer | Open-market purchase | Common Warrant | 5,700 | - | - | |
| John B. Henneman III - Director | Grant or award | Common Stock | 1,045 | $0.00 | - | |
| John B. Henneman III - Director | Grant or award | Stock Options (Right to Buy) | 4,185 | $0.00 | - | |
| Marc Duey - Director | Open-market sale | Common Stock | 6,462 | $4.58 | $30K | |
| Oren Gilad - Officer | Open-market purchase | Common Stock | 500 | $3.92 | $2K | |
| Marc Duey - Director | Open-market purchase | Common Stock | 30,000 | $4.39 | $132K | |
| Oren Gilad - Officer | Open-market purchase | Common Stock | 250 | $2.90 | $725 | |
| John P. Hamill - Officer | Open-market purchase | Common Stock | 50 | $2.46 | $123 | |
| Marc Duey - Director | Open-market purchase | Common Stock | 190 | $2.58 | $490 | |
| Bernd R. Seizinger - Director | Open-market purchase | Common Stock | 10,000 | $2.68 | $27K | |
| John P. Hamill - Officer | Open-market purchase | Common Stock | 450 | $2.61 | $1K | |
| Oren Gilad - Officer | Open-market purchase | Common Stock | 150 | $2.54 | $381 | |
| Oren Gilad - Officer | Open-market purchase | Common Stock | 1,000 | $2.59 | $3K |
Aprea Therapeutics, Inc. (APRE) had 8 insider filings in the last 90 days, with the most recent on 2026-06-17. The full record for APRE runs to 24 Form 4 filings, the earliest from 2024-10-15. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of APRE were filed in the last 90 days. 17 purchases are on record for this company.
No insider sales of APRE were filed in the last 90 days. 1 sale is on record for this company.
This page tracks APRE Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add APRE to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
